

**WOODHOLME GASTROENTEROLOGY ASSOCIATES, P.A.**

Board Certified in Gastroenterology  
Practice Limited to Gastroenterology and Liver Disease

EDWARD J. WOLF, M.D.  
TODD D. HELLER, M.D.  
LOC T. LE, M.D.  
EDWARD D. ZIMMERMAN, M.D.

LILA TARMIN, M.D.  
MICHAEL S. SIUTA, M.D.  
GERALD A. HOFKIN, M.D.

November 16, 2000

Jane Henney, M.D  
Commissioner, Food and Drug Administration  
Docket No. 00P-1499/CPI  
Dockets Management Branch  
Food and Drug Administration  
Department of Health and Human Services, Room 1-23  
12420 Parklawn Drive  
Rockville, Maryland 20857

8 7 5 0 ' 0 0 NOV 17 P 1 : 3 8

Dear Dr Henney:

As part of one of the largest Gastroenterology groups in the Baltimore, MD area, I am writing to you regarding the review of Lotronex that is taking place before the FDA. I feel this medication has tremendous benefits when prescribed for the appropriate patient and should remain part of our armamentarium when treating the very difficult irritable bowel syndrome patient. To date these patients are extremely difficult to satisfy and Lotronex is extremely helpful in treating these diarrhea predominant patients.

We respectfully request that the FDA continue to permit Lotronex as part of our prescribing regiment. We are aware of the constipation side effects and how to effectively treat it. My practice has many patients who have benefited from the medication and they will be extremely disappointed if this medication were no longer available. I would be happy to provide additional information regarding our use of Lotronex. Thank you for your consideration.

Sincerely,



Bethany McGarr, M.S., P.A.

00P-1499

234